[Edaily Reporter Kim Kyung-eun ] SK hynix(000660)hit an all-time high, surpassing 3 million won in pre-market trading.
SK hynix’s stock price is displayed on an electronic board in the Hana Bank dealing room in Jung-gu, Seoul, on the 22nd, the day the company rose to become the top company by market capitalization on the KOSPI. (Photo = Newsis)
According to Nextrade on the 23rd, SK hynix was trading at 2.97 million won as of 8:15 a.m. that day, up 1.75% from the previous trading day. It briefly soared to 3,002,000 won during pre-market trading.
SK hynix surpassed SamsungElectronics(005930)the previous day to claim the top spot in market capitalization on the KOSPI. Based on the closing price, SK hynix’s market capitalization stands at 2,080.3782 trillion won. SamsungElectronics’ common stock market capitalization was recorded at 2,066.6595 trillion won.
This reversal is interpreted as a result of shifts in the semiconductor industry landscape driven by expanded investment in artificial intelligence (AI). This is because SK hynix has secured a leading position in the AI memory market by supplying High Bandwidth Memory (HBM) to major clients such as NVIDIA.
Anticipation surrounding the listing of American Depositary Receipts (ADRs) is also boosting investor sentiment. The market expects a Nasdaq listing as early as next month.
With the second-quarter earnings season approaching in July, the possibility of further gains is also being discussed.
Park Jun-young, an analyst at HANWHA INVESTMENT & SECURITIES, said, “SK hynix’s 12-month forward price-to-earnings ratio (PER) stands at 6.6x, which remains low compared to global semiconductor companies,” adding, “Earnings stability is improving based on long-term supply contracts for HBM.”
Jeonbuk Bank, a subsidiary of JB Financial Group Co., Ltd.(175330), has become the first bank in South Korea to introduce won-denominated loans linked to digital assets. Initially, the service will be…
GENINUS Inc.(389030)is embarking on experimental research to verify the feasibility of developing actual treatments based on new anti-cancer drug targets identified using artificial intelligence (AI).…
#Onconic Therapeutics Inc. has unveiled a new drug candidate designed to reduce muscle loss that can occur during weight loss when used in combination with existing glucagon-like peptide-1 (GLP-1) cla…